Check Claims Before You Publish

Quick quantitative appraisal (data source: OpenAlex extract you provided)

• Total works (provided): 447
• Total citations (provided): ~26,990
• h-index (provided): 68
• Top topics (OpenAlex tags): Medicine, Biology, Virology, HIV, Internal medicine

Representative high-impact works (evidence of clinical and translational influence)

Roger Paredes appears on large, high-impact clinical and translational papers (examples below). These works indicate engagement in clinical trials and HIV/viral infectious disease research and collaborations with major groups:

• Remdesivir NEJM (2020)
• Remdesivir PINETREE (2021)
• HIV gut microbiome (2019)

Qualitative strengths and evidential notes

• High productivity and sustained output across decades (many years with >10 works/year in 2010s–2020s) shown in the plots above — consistent with an active research program and broad collaborations.
• Substantial citation impact and h-index (68) indicate many works with lasting influence; participation in high-profile clinical trials (NEJM) supports translational reach and multi-center collaboration capacity Remdesivir NEJM (2020).
• Topical breadth: clinical infectious diseases (HIV, COVID-19, mpox) and microbial ecology/host–microbe interactions; this breadth can confer higher translational value but requires multidisciplinary rigor (clinical trials, cohort studies, multi-omics).

Potential limitations, blindspots, and bias checks

• Large multi-author papers (high-impact trials) are collaborative: individual contribution intensity can vary — author-level metrics (works_count, cited_by_count, h-index) reflect visibility but not alone the depth/leadership of conceptual contributions.
• Topic areas like HIV and microbiome are susceptible to confounding (diet, geography, cohort composition). For example, the 2019 microbiome study notes geographic Prevotella-rich context and missing dietary data as limitations that may limit generalizability Microbiome study limitations.
• Publication and citation counts do not reveal conflicts of interest or funding influences; each high-impact clinical trial should be inspected individually for sponsor roles and COI declarations (the NEJM remdesivir ACTT-1 trial was NIAID-funded; PINETREE had Gilead funding disclosed in the manuscript) PINETREE funding note.

Conclusions (evidence-weighted)

1. Roger Paredes' author-level metrics from OpenAlex (high works_count, high citations, h-index 68) and co-authorship on multiple high-impact clinical trials and cohort studies indicate a scientifically influential author with broad clinical and translational reach.
2. Strength comes from consistent productivity, presence on high-quality randomized trials (NEJM) and multi-omic cohort studies; potential blindspots include co-author contribution heterogeneity, domain-specific confounders (microbiome studies), and the normal need to inspect COI/funding on a per-paper basis.
3. Overall confidence: moderate-to-high that Paredes is a productive, influential clinical/viral-infectious-disease researcher with demonstrable contributions to trials and cohort studies; the exact weight of his intellectual leadership per paper requires per-manuscript inspection (author position, corresponding author status, and declared contributions).

Selected citations used in this review

• Remdesivir NEJM (2020)
• Remdesivir PINETREE (2021)
• HIV gut microbiome (2019)